Rivastigmine
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
Rivastigmine: From Unspecified Original Indication to Glaucoma
One-Sentence Summary
Rivastigmine’s original approved indication is not specified in the current evidence pack (data gap), though it is a well-known dual acetylcholinesterase/butyrylcholinesterase inhibitor. The TxGNN model predicts it may be effective for Glaucoma, with 0 clinical trials and 3 publications (including one animal IOP study) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in evidence pack (no license/indication data available) |
| Predicted New Indication | Glaucoma |
| TxGNN Prediction Score | 99.27% |
| Evidence Level | L4 |
| India Market Status | Not Marketed (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action (MOA) data for rivastigmine is not available in the current evidence pack (flagged as data gap DG002). However, the repurposing rationale accompanying this prediction indicates that rivastigmine is a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), which increases local acetylcholine concentration.
Elevated acetylcholine can induce ciliary muscle contraction and pupillary miosis, which in turn increases aqueous humor outflow through the trabecular meshwork — a mechanism pharmacologically analogous to established cholinergic IOP-lowering agents such as pilocarpine and physostigmine. This represents a plausible class-effect extension of rivastigmine’s known cholinesterase-inhibiting activity to an ophthalmic indication.
This mechanistic link remains an indirect inference. No human intraocular pressure (IOP) data currently exist for rivastigmine, and similarity to any original approved indication cannot be assessed since original indication data is absent from this evidence pack. One preclinical (rabbit) study did show topical rivastigmine lowers IOP, which lends preliminary support to the hypothesis, but translation to human efficacy and safety remains unconfirmed.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10673128 | 2000 | Animal Study (Preclinical, rabbit model) | J Ocular Pharmacol Ther | Topical rivastigmine, a selective AChE inhibitor, lowered intraocular pressure in normotensive rabbits over an 8-hour monitoring period |
| 27967267 | 2017 | Review (Patent Literature) | Expert Opin Ther Patents | Mild AChE inhibition has recognized therapeutic relevance in Alzheimer’s disease, myasthenia gravis, and glaucoma; reviews patent landscape for AChE inhibitors/reactivators |
| 39130374 | 2024 | Review (Systems Genetics/Molecular) | Front Mol Biosci | Reviews cholinergic (muscarinic receptor-mediated) mechanisms regulating intraocular pressure via the trabecular meshwork, contextualizing cholinesterase-inhibitor approaches |
Safety Considerations
Drug Interactions: A total of 170 interactions were identified in the DDI database. Selected examples include:
| Interacting Drug | Severity |
|---|---|
| Bupropion | Major |
| Famotidine | Moderate |
| Ranitidine | Moderate |
| Cimetidine | Moderate |
| Clarithromycin | Moderate |
| Metronidazole | Moderate |
| Levofloxacin | Moderate |
| Atropine | Moderate |
| Hyoscyamine | Moderate |
| Dicyclomine | Moderate |
| Glycopyrronium | Moderate |
| Trospium | Moderate |
| Loperamide | Moderate |
| Dolasetron | Moderate |
| Palonosetron | Moderate |
Note: anticholinergic agents (atropine, hyoscyamine, dicyclomine, glycopyrronium, trospium, mepenzolate, clidinium) may pharmacodynamically antagonize rivastigmine’s cholinergic effect. Formal key warnings and contraindications are not yet available in this evidence pack (data gap DG001, blocking) — please refer to the official package insert once obtained.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for glaucoma is currently limited to mechanistic reasoning and a single preclinical (rabbit) IOP study — no human clinical trials exist, and the drug is not marketed in India (0 registrations). Combined with a blocking data gap on official safety labeling, the evidence base does not yet support advancing beyond preliminary screening (S0).
To proceed, the following is needed:
- TFDA/CDSCO-equivalent package insert with formal warnings and contraindications (DG001, blocking)
- Confirmed mechanism of action documentation from DrugBank (DG002)
- Original approved indication data to establish original-to-new indication similarity
- Human proof-of-concept data (Phase 1/2) on ocular safety and IOP-lowering efficacy, given rivastigmine’s known systemic cholinergic side-effect profile
- Route compatibility assessment — existing rivastigmine formulations (oral, transdermal patch) are not ocular-route products; a topical ophthalmic formulation would need to be developed and characterized
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.